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G-banding - Top: Courtesy Jean Luc Lai; Bottom: Courtesy Melanie Zenger and Claudia Haferlach. 
 
Clinics and pathology 
Disease 
t(6;14)(p21.1;q32.3) is mainly multiple myeloma / 
plasma cell leukaemia, but also observed in diffuse 
large B cell non Hodgkin lymphoma (DLBCL) and 
marginal zone B cell lymphoma. 
Phenotype/cell stem origin 
Mature B-lymphocyte. 
Epidemiology 
Approximately 4% of primary MM cases. MGUS? 
Should be rather frequent in lymphoma but not yet 
systematically estimated. 
Cytology 
CD138+ dystrophic or not dystrophic plasma cells in 
MM; CD5+ diffuse large B cell lymphoma and splenic 
lymphoma with villous lymphocytes in NHL. 
Prognosis 
No prognosis value clearly established. 
Cytogenetics 
Cytogenetics morphological 
May be not easy to detect. 










Translocation detected by FISH with CCND3 and IgH 
probes; der(14) sometimes in multiple copies; der(6) 
sometimes lost. 
Additional anomalies 
Complex karyotype in most cases. 
Genes involved and proteins 






6,88kb, 5 exons, 5¹ - 3¹ telomeric orientation. 
Protein 
32,5kDA, 292 amino acids; regulates Rb1 
phosphorylation and, hence, cell cycle G1/S transition, 









6p21.1 breakpoint centromeric to CCND3; 14q32.3 
breakpoint in the switch region; leads to proximity 








Dysregulation and overexpression of CCND3. 
To be noted 
Case Report 
A case of Chronic Lymphocytic Leukemia (CLL) with 
a rare chromosome abnormality: 
t(1;14;6)(q21;q32;p21), a variant of t(6;14)(p21;q32). 
A case of Chronic Lymphocytic Leukemia (CLL) with 
a rare chromosome abnormality: 
t(1;14;6)(q21;q32;p21), a variant of t(6;14)(p21;q32). 
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